Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Samsung Electro-mechanics Co., Ltd.

Sungkyunkwan University

Skaichips Co., Ltd.

Min Young Kim

Se Chang Kwon

Sung Youb Jung

Sung Min Bae

Dae Jin Kim

Sung H Hong

Kang Yoon Lee

Myung Hyun Jang

Hyung Kyu Lim

Young Gun Pu

Jong Wan Jo

Dong Soo Park

Kyung Duk Choi

Jae Yeol Choi

Young Jin Park

Gwan Sun Lee

Jaehyuk Choi

In Young Choi

Jin Mo Ahn

Hyun Uk Kim

Dae Hae Song

Chang Ki Lim

Sung Hee Park

Euh Lim Oh

Jin Sun Kim

Dae Seong Im

Yong Ho Huh

Byeong Gi Jang

Jin-Sun Kim

Eun Hee Kang

Jong-soo Lee

Sung Hee Hong

As inputs of a controller of a direct current (DC)-DC converter are sampled for a predetermined time and thus two-dimensional state information in which one axis is an input physical quantity and the other axis is a time is generated, the two-dimensional state information is processed by a convolutional neural network to determine and output one of a plurality of control signals. An artificial intelligence control part may operate in accordance with a plurality of operation conditions or dynamically determined operation conditions by applying different artificial intelligence engines according to operation modes.

DC-DC converter with intelligent controller

A current sensor automatically adjusting an offset voltage, includes an input corrector, upon receiving a first voltage, a second voltage, and a control signal, configured to correct either one or both of the first voltage and the second voltage to reduce an absolute value of a difference between the first voltage and the second voltage based on the control signal, and output a correction result; an input amplifier configured to amplify a voltage output from the input corrector; an output amplifier configured to generate an output voltage when a voltage amplified by the input amplifier is input; a controller including a switch connected to one of voltages amplified by the input amplifier to be grounded when a difference between the first voltage and the second voltage is larger than a first threshold value; and a correction circuit controller configured to generate the control signal to input to the input corrector.

Current sensor capable of automatic adjustment of offset voltage

A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

Long-acting conjugates of GLP-2 derivatives

Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance.

Process for preparation of physiologically active polypeptide complex

The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.

Liquid formulation of long-acting insulin conjugate

A method for preparing a conjugate by linking a physiologically active polypeptide, a non-peptidyl polymer linker, and an immunoglobulin constant region via a covalent bond are disclosed. The method enables an efficient preparation of a physiologically active polypeptide conjugate, in which a salt is used in a coupling reaction to improve the problem of low production yield during preparation of the physiologically active polypeptide conjugate.

Preparation method for high-yield production of physiologically active polypeptide conjugate

Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form.

Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same

A power inductor includes: a substrate on which an internal electrode coil pattern is formed; and composite layers formed by alternately stacking first sheets formed of a mixture of coarse metal powder and fine metal powder and second sheets formed of fine metal powder on the internal electrode coil pattern of the substrate, thereby obtaining high inductance.

Power inductor and method of manufacturing the same

The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.

Long-acting interferon beta formulation comprising an immunoglobulin fragment

The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment intosp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use ofor animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same

Disclosed is a liquid formulation which allows long-acting EPO conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting EPO conjugates.

Liquid formulations for long-acting erythropoietin conjugate

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate

Growing community of inventors

Suwon-si, South Korea

Min Young Kim